TWI830151B - 抗GPRC5DxBCMAxCD3三特異性抗體及其用途 - Google Patents

抗GPRC5DxBCMAxCD3三特異性抗體及其用途 Download PDF

Info

Publication number
TWI830151B
TWI830151B TW111106048A TW111106048A TWI830151B TW I830151 B TWI830151 B TW I830151B TW 111106048 A TW111106048 A TW 111106048A TW 111106048 A TW111106048 A TW 111106048A TW I830151 B TWI830151 B TW I830151B
Authority
TW
Taiwan
Prior art keywords
antibody
antigen
domain
amino acid
seq
Prior art date
Application number
TW111106048A
Other languages
English (en)
Chinese (zh)
Other versions
TW202237661A (zh
Inventor
偉 徐
沈灣灣
李莉
王旋
陳娟 朱
Original Assignee
大陸商信達生物製藥（蘇州）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商信達生物製藥（蘇州）有限公司 filed Critical 大陸商信達生物製藥（蘇州）有限公司
Publication of TW202237661A publication Critical patent/TW202237661A/zh
Application granted granted Critical
Publication of TWI830151B publication Critical patent/TWI830151B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW111106048A 2021-02-19 2022-02-18 抗GPRC5DxBCMAxCD3三特異性抗體及其用途 TWI830151B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110189359.8 2021-02-19
CN202110189359 2021-02-19

Publications (2)

Publication Number Publication Date
TW202237661A TW202237661A (zh) 2022-10-01
TWI830151B true TWI830151B (zh) 2024-01-21

Family

ID=82932102

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111106048A TWI830151B (zh) 2021-02-19 2022-02-18 抗GPRC5DxBCMAxCD3三特異性抗體及其用途

Country Status (8)

Country Link
US (1) US20250074996A1 (enExample)
EP (1) EP4296286A4 (enExample)
JP (1) JP2024510098A (enExample)
CN (1) CN116897166A (enExample)
AU (1) AU2022223152B2 (enExample)
CA (1) CA3211407A1 (enExample)
TW (1) TWI830151B (enExample)
WO (1) WO2022174813A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022068809A1 (zh) * 2020-09-29 2022-04-07 信达生物制药(苏州)有限公司 抗cd3抗体以及其用途
WO2022175255A2 (en) 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
WO2023236889A1 (zh) * 2022-06-06 2023-12-14 山东先声生物制药有限公司 靶向bcma、gprc5d和t细胞的多特异性抗体及其应用
EP4585615A4 (en) * 2022-09-09 2026-07-08 Beijing Mabworks Biotech Co Ltd Multispecific antibody binding to BCMA, GPRC5D and CD3 and its use
CN117924485A (zh) * 2022-10-25 2024-04-26 上海祥耀生物科技有限责任公司 一种抗gprc5d的多特异性抗体
TW202434644A (zh) 2023-02-07 2024-09-01 大陸商上海齊魯製藥研究中心有限公司 三特異性抗原結合分子及其應用
EP4725970A1 (en) 2023-06-06 2026-04-15 Fortvita Biologics Inc. Preparation and use of anti-gprc5d/bcma/cd3 trispecific antibody
WO2025056013A1 (zh) * 2023-09-13 2025-03-20 江苏恒瑞医药股份有限公司 一种包含特异性结合gprc5d和cd3的双特异性抗体的药物组合物
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
AU2024370890A1 (en) 2023-10-30 2026-06-11 Leads Biolabs Inc. Antibody binding to bcma and multispecific antibody comprising same
CN122349420A (zh) * 2023-12-04 2026-07-07 山东先声再明生物制药有限公司 一种多特异性抗体的组合物及其制备方法和应用
WO2025134050A1 (en) * 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
WO2025134049A1 (en) * 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
WO2025131077A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3多特异性抗体及用途
CN117843788B (zh) * 2024-01-09 2025-02-11 四川大学 一种抗gprc5d的抗体及其多特异性抗体和相关应用
CN120647761A (zh) * 2024-03-15 2025-09-16 信达生物制药(苏州)有限公司 抗dll3抗体及其用途
WO2025194478A1 (en) * 2024-03-22 2025-09-25 Biofront Ltd Antibodies binding to cd3 and gprc5d, and uses thereof
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2026026893A1 (zh) * 2024-08-01 2026-02-05 上海齐鲁制药研究中心有限公司 结合人gprc5d/bcma/cd3的三特异性抗体制剂及其用途
WO2026109053A1 (zh) * 2024-11-25 2026-05-28 江苏恒瑞医药股份有限公司 特异性结合bcma、gprc5d和cd3的抗原结合分子及其医药用途
WO2026119236A1 (zh) * 2024-12-05 2026-06-11 信达生物制药(苏州)有限公司 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途
WO2026149576A1 (zh) * 2025-01-13 2026-07-16 上海橙帆医药有限公司 多特异性抗体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201809005A (zh) * 2016-07-20 2018-03-16 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
US20190352416A1 (en) * 2014-12-22 2019-11-21 Xencor, Inc. Trispecific antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
SG176219A1 (en) * 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
EP3297672B1 (en) * 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
CN109069638B (zh) * 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
WO2019005637A2 (en) * 2017-06-25 2019-01-03 Systimmune, Inc. MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
CN113811546B (zh) * 2019-05-07 2025-03-11 免疫里森公司 前体三特异性抗体构建体及其使用方法
CN112062851B (zh) * 2019-06-11 2022-09-09 南京驯鹿医疗技术有限公司 靶向bcma嵌合抗原受体的抗体及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190352416A1 (en) * 2014-12-22 2019-11-21 Xencor, Inc. Trispecific antibodies
TW201809005A (zh) * 2016-07-20 2018-03-16 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
期刊 Guido Lancman et al, "Bispecifics, trispecifics, and other novel immune treatments in myeloma", Hematology Am Soc Hematol Educ Program. 2020 Dec 4; 2020(1): 264–271.
期刊 Guido Lancman et al, "Bispecifics, trispecifics, and other novel immune treatments in myeloma", Hematology Am Soc Hematol Educ Program. 2020 Dec 4; 2020(1): 264–271.; *
期刊 R. Castoldi, U. Jucknischke et al, "Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties", Protein Engineering, Design & Selection vol. 25 no. 10 pp. 551–559, 2012. *

Also Published As

Publication number Publication date
CA3211407A1 (en) 2022-08-25
US20250074996A1 (en) 2025-03-06
JP2024510098A (ja) 2024-03-06
TW202237661A (zh) 2022-10-01
EP4296286A1 (en) 2023-12-27
EP4296286A4 (en) 2025-09-17
CN116897166A (zh) 2023-10-17
WO2022174813A1 (zh) 2022-08-25
AU2022223152B2 (en) 2026-02-19
AU2022223152A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
AU2022223152B2 (en) Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
US9884921B2 (en) Bispecific heterodimeric diabodies and uses thereof
US11639393B2 (en) Anti-CCR8 antibodies
US20250092135A1 (en) Antibody and use thereof
CN119173528A (zh) 针对cd277和肿瘤抗原的双特异性抗体
CN115558023A (zh) 抗cd3抗体及其用途
TW202346337A (zh) Ilt3及cd3結合劑以及其使用方法
US20240141071A1 (en) Antibodies that bind cd123 and gamma-delta t cell receptors
KR20250040586A (ko) 감마-델타 t 세포 수용체에 결합하는 변이체 항체
WO2024251154A1 (zh) 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途
WO2024235317A1 (zh) 结合lilrb4和cd3的抗体及其用途
WO2025077831A1 (en) Anti-il-4ra/tslp antibodies and uses thereof
WO2025083273A1 (en) Binding molecules
CN118846036A (zh) 一种包含特异性结合cd3和muc16的双特异性抗体的药物组合
WO2025092742A1 (zh) 结合bcma的抗体以及包含其的多特异性抗体
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
WO2024051804A1 (zh) 抗ilt4抗体及其医药用途
CA3294164A1 (en) Preparation of anti-gprc5d/bcma/cd3 trispecific antibody and use thereof